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ABSTRACT 
Fibromyalgia (FM) is difficult to diagnose and manage chronic pain condition whose symptoms 
have no clear pathophysiological cause, although it is thought that patient hypersensitivity to a 
range of stimuli may give rise to mechanical hyperalgesia as a result of altered central nociceptive 
processing. The 1990 American College of Rheumatology (ACR) classification criteria, which have 
been widely used in clinical practice, require the existence of chronic widespread pain (CWP) for 
> 3 months, and the presence of at least 11 out of 18 specified tender points upon digital palpation, 
although this latter criterion has long been criticised. The newer 2010 ACR diagnostic criteria state 
that FM can be defined as CWP associated with somatic symptoms, and recommend the use of a 
widespread pain index and a scale to rate symptom severity. A modified version of the 2010 criteria 
removed the physician assessment of the extent of somatic symptoms and replaced it by a summary 
score of three self-reported symptoms, thus making it easier to use while maintaining its sensitivity. 
This review discusses the advantages and limitations of all of these criteria 
 
 INTRODUCTION 
Fibromyalgia (FM) is characterised by chronic widespread pain (CWP) and a range of other 
symptoms [1]. It is difficult to diagnose because FM has no specific diagnostic marker and, although 
CWP predominates, its symptoms are non-specific and may be due to various causes; furthermore, 
it can frequently overlap with central sensitivity syndrome [1], [2]. It has now become clear that 
psychological factors are less important than was originally thought: some patients may have 
concomitant psychiatric disorders but many do not, and the simultaneous presence of other pain 
and somatic syndromes is more frequently found in twin and epidemiological studies [2]. 
 
The 1990 American College of Rheumatology (ACR) classification criteria have been extensively 
used in clinical practice [3]. These require a 3-month history of CWP on both sides of the body, 
above and below the waist, that also involves the upper and/or lower spine; they also require the 
presence of > 11 out of 18 secified sites that are tender upon digital palpation. The newer 2010 
ACR criteria state that FM is characterised by CWP associated with fatigue, sleep and cognitive 
disturbances, and a range of somatic symptoms[4], and use a widespread pain index and a scale for 
rating the severity of fatigue, sleep disorders, dyscognition, and 41 possible somatic symptoms. A 
modified version of the 2010 criteria removed the physician estimate of the extent of somatic 
symptoms and replaced it with a summary score of three self-reported symptoms, thus making it 
easier to use while maintaining its sensitivity [5]. In comparison with their predecessors, these 
modified criteria indicate a greater prevalence of FM with a higher proportion of male 
patients [6], [7]. 
 
This review discusses the advantages and limitations of the three sets of criteria with the aim of 
identifying the criteria that are more likely to lead the correct diagnosis of FM. 
 
ARE THE 2010 ACR CRITERIA BETTER THAN THE 1990 ACR CRITERIA? YES 
OF COURSE 
 
The 1990 ACR criteria [4] have contributed greatly to harmonising study populations in order to 
facilitate research and, although initially developed as “classification” criteria, have been widely 
used to diagnose FM in clinical practice. However, there were criticisms of their inclusion of tender 
points because there is no specific pathology at the given sites, reduced pressure pain thresholds are 
not limited to these points and, in any case, are lower in females then males, the tenderness reflects 
distress rather than the pressure pain threshold itself, and the cut-off value of 11 tender points is 
diagnostically insensitive. 
 
Granges et al. used an algometer to measure pressure pain thresholds in patients with FM 
or regional pain syndrome, and healthy pain-free subjects [8]. Although the FM patients had lower 
thresholds at the tender point sites than the patients with regional pain syndrome or pain-free 
subjects, the mean thresholds at control points were also lower, thus showing that reduced pressure 
pain thresholds are not restricted to specific sites. 
 
Maquet et al. [9] used an algometer to investigate gender differences in pressure pain thresholds, and 
found that healthy normal females had significantly lower pressure pain thresholds than their male 
counterparts at all of the FM tender point sites, thus indicating that females are generally more 
likely to meet the tender point criterion. 
 
In 1997, Wolfe et al. [10] showed that the number of tender point in FM patients significantly 
correlated with the rheumatology distress index (0.55, p < 0.05) whereas correlation with 
algometer-measured pressure pain pressure was lower (0.52, < 0.05) [1]. This suggested that tender 
point counts measure distress more than pressure pain thresholds. 
 
Katz et al. compared the 1990 ACR criteria with epidemiology-based criteria and clinical diagnoses 
made by a rheumatologist experienced in FM [11] in > 200 consecutive patients with a diagnosis of 
FM recruited in a setting of routine clinical practice, and found only a moderate degree of 
agreement. The diagnoses based on the three sets of criteria were unanimous in only 33% of cases. 
Using the diagnosis of the rheumatologist as the gold standard, they found that the cut-off value of 
11/18 tender points was highly specific but had a diagnostic sensitivity of no > 50%; Furthermore, 
reducing the number to eight tender points improved sensitivity to 70% without significantly 
affecting specificity. 
 
In addition to the controversy associated with tender point counts, it needs to be remembered that 
pain and tenderness are not the only symptoms in FM. Fatigue, sleep disturbances, stiffness and 
cognitive impairment are all frequent [12], together with other co-morbidities, depression, irritable 
bowel syndrome, restless leg syndrome and migrane [1]. An international survey has shown that 
> 90% of FM patients suffer from fatigue and > 80% from sleep disturbances [12] and, as these 
symptoms are so frequent, it is difficult to understand why they did not form part of the diagnostic 
criteria. 
 
From the time of symptom onset to a diagnosis of FM can take more than two years [12], with the 
patients having to consult an average of three physicians. A study based on a general practice 
research database in the UK has shown that the pre-diagnosis use of healthcare resources (including 
diagnostic tests and specialist referrals) is significantly higher in patients with FM than controls [13] 
and that, given the reduction in such use decreases after FM has been diagnosed, delayed diagnosis 
is associated with increased healthcare costs. Studies in the USA [14] and Europe [15] have also 
shown that healthcare use is 2–3 times greater in the case of FM patients than in the case of controls 
and, as the prevalence of FM is 2–5% [16], [17], [18], it can be considered a major healthcare burden. 
 
Given the sheer number of FM patients, the 2012 Canadian Pain Society/Canadian Rheumatology 
Association guidelines for the diagnosis and management of FM recognise that rheumatologists 
cannot manage all FM patients [19]. These guidelines recommended using the ACR 2010 
criteria [4] and, more specifically, state that “an examination of soft tissues for generalised 
tenderness should be performed by manual palpation with the understanding that the specific tender 
point examination according to the 1990 ACR diagnostic criteria is not required to confirm a 
diagnosis of FM. FM should depend on the clinical evaluation of individual patients that may 
suggest some other medical condition. The primary care physician should establish a diagnosis of 
FM as early as possible without the need for confirmation by a specialist, and communicate this 
diagnosis to the patient. Repeated investigations after diagnosis should be avoided unless driven by 
the onset of new symptoms and signs on physical examination.” 
 
In brief, FM is common and an enormous healthcare burden. A delayed diagnosis is costly, and 
primary care physicians should be trained to recognise the condition. ACR 2010 criteria [6] facilitate 
this by removing the need to examine specific tender points as these reflect distress rather than 
pressure pain thresholds and lead to under-diagnosis in men. 
 
ARE THE 2010 ACR CRITERIA BETTER THAN THE 1990 ACR CRITERIA? NO 
OF COURSE NOT 
 
The 2010 criteria [4] replaced the tender point physical examination with a widespread pain index 
(WPI, a 0–19 count of the number of reportedly painful body regions), and introduced a 0–3 
severity scale for the characteristic symptoms of fatigue, unrefreshing sleep and cognitive problems, 
and the extent of somatic symptom reporting, which were combined to give a 0–12 symptom 
severity (SS) score, and led to a new definition of FM as a WPI of > 7 and an SS > 5, or a WPI of 
3–6 and an SS of > 9. The underlying purpose of these criteria were to simplify diagnosis; offer 
guidelines suitable for use in primary care practice; acknowledge the importance of the many non-
painful symptoms of FM, such as fatigue, sleep disorders and perceived cognitive impairment 
(“fibrofog”); and provide a means of assessing disease severity and developing a method of 
longitudinal patient monitoring. They also changed the definition of FM from a “peripheral pain-
defined disease” to a “systemic symptom-based disease”. 
 
Wolfe et al. proposed modifying the 2010 ACR criteria by introducing what we call the 2011 
criteria [5], which replaced the physician assessment of the extent of somatic symptoms with an item 
(scored 0–3) representing the sum of the presence/absence of headache, lower abdominal pain or 
cramps, and depressive symptoms during the previous six months. They also introduced the use of 
patient-reported areas of “pain or tenderness” for the WPI, whereas this assessment was restricted to 
physicians in the ACR 2010 criteria. These changes were suggested because it had been shown that 
a quarter of all FM patients failed to satisfy the 1990 ACR classification criteria [6]; however, the 
new criteria did not overcome this limitation as their exclusion of inflammatory and other painful 
disorders means that they cannot be applied in the case of patients with rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE), or other similar conditions [20], [21], [22], and do not distinguish 
primary and secondary FM. Furthermore, a 2010 criteria-based diagnosis requires a physician's 
evaluation of the extent and severity of a patient's somatic symptoms, and it is likely that the 
absence of the need for a physical examination will lead to possibly important physical findings and 
other potential causes of symptoms being overlooked [6], [7]. Finally, even though no objective 
parameters are currently used in routine clinical practice, the 2011 criteria and do not include the 
results of any laboratory or imaging examination [6], [7]. 
 
Consequently, both the 2010 and 2011 criteria can be faulted on the grounds that they are poorly 
defined and are totally reliant on the assessment of symptoms as they do not include any evaluation 
of mechanistic factors [7]. FM needs to be diagnosed on a clinical evaluation of individual patients, 
whereas these criteria may also apply to other medical conditions. Furthermore, the co-existence of 
ACR classification criteria, a WPI of 7 and an SS score of 5, a WPI of 3–6 and an SS score of 9, 
and personal opinion is not only confusing in itself, but there is also a risk that the polysymptomatic 
distress scale may not reflect the severity of FM symptoms, which may be better defined on the 
basis of mechanical hyperalgesia (i.e. tender point counts).. 
 
Jones et al. [23] have shown that estimates of the prevalence of FM vary depending on the criteria 
used: 1.7% (95% confidence interval [CI] 0.7–2.8) on the basis of the 1990 criteria; 1.2% (95% CI 
0.3–2.1) on the basis of the 2010 criteria; and 5.4% (95% CI 4.7–6.1) on the basis of the 2011 
criteria, which also identify a higher proportion of men. 
 
CONCLUSIONS 
FM is frequently encountered and represents a considerable burden on healthcare resources. 
Although experts are still seeking the best diagnostic criteria, particularly for early-onset disease, 
the costs of a delayed diagnosis mean that primary care physicians should be trained to recognise 
and manage it promptly. The new 2010, modified 2011 or, even better the 2016 diagnostic 
criteria [24] which are further step forward, include a symptom severity scale and CWP index that 
more appropriately reflect the multifaceted aspects of the syndrome. However, the question as to 
whether CWP is the sine qua non or may be combined with other symptoms reflecting different 
stages of a central sensitisation syndrome remains, and may only be answered by the discovery of a 
clinical or biological marker that can identify the population affected by, or at risk of developing 
FM. 
 
TAKE-HOME MESSAGES 
 The 1990 ACR classification criteria define FM as chronic widespread pain with 
pressure pain allodynia or hyperalgesia. 
 The new 2010 and modified 2011 ACR diagnostic criteria also include a symptom 
severity scale that better reflects the multifaceted mature of the syndrome. 
 The 1990, 2010 and 2011 ACR criteria have advantages and limitations 
 There is still a lack of a specific biomarker in the direction of identifying this multi-
symptom syndrome. 
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